Cabozantinib
Encyclopedia
Cabozantinib is a small molecule
inhibitor of the tyrosine kinases Met
and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis.
It is being developed by Exelixis
Inc.
Cabozantinib was granted orphan-drug
status by the FDA in January 2011.
It is currently in a number of clinical trials for prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular, kidney, and medullary thyroid cancer.
Positive data from clinical trials indicate Cabozantinib is particularly beneficial in metastatic advanced prostate cancer. 97% of patients either had stabilization or improvement in bone malignancies. The median time to disease progression was 29 weeks.
One US trial reported in May 2011 : The best results were seen in patients with liver, prostate, and ovarian cancer: 22 of 29 patients with liver cancer, 71 of 100 patients with prostate cancer, and 32 of 51 with ovarian cancer experienced either partial tumor shrinkage or stable disease.
Fifty-nine out of 68 patients who had bone metastases had their metastases shrink or disappear during the trial.
Small molecule
In the fields of pharmacology and biochemistry, a small molecule is a low molecular weight organic compound which is by definition not a polymer...
inhibitor of the tyrosine kinases Met
Met
-In the arts:* Metropolitan Opera in Manhattan, New York* Metropolitan Museum of Art in Manhattan, New York* Various buildings known as the Metropolitan Opera House* The Metropolitan Ensemble Theater in Kansas City, Missouri-In computing and the Internet:...
and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis.
It is being developed by Exelixis
Exelixis
Exelixis is a genomics-based drug discovery company located in South San Francisco, Ca. It works on the development of anti-cancer therapies. Exelixis has several compounds in various stages of FDA approval including :...
Inc.
Cabozantinib was granted orphan-drug
Orphan drug
An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease...
status by the FDA in January 2011.
It is currently in a number of clinical trials for prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular, kidney, and medullary thyroid cancer.
Positive data from clinical trials indicate Cabozantinib is particularly beneficial in metastatic advanced prostate cancer. 97% of patients either had stabilization or improvement in bone malignancies. The median time to disease progression was 29 weeks.
One US trial reported in May 2011 : The best results were seen in patients with liver, prostate, and ovarian cancer: 22 of 29 patients with liver cancer, 71 of 100 patients with prostate cancer, and 32 of 51 with ovarian cancer experienced either partial tumor shrinkage or stable disease.
Fifty-nine out of 68 patients who had bone metastases had their metastases shrink or disappear during the trial.